ArsenalBio Takes In $85 Million In Series A To Develop Cancer-Fighting Immunotherapies

Initially formed as a shell company with seed financing in 2018, a year later ArsenalBio has emerged with an $85 million Series A round to finance its development of cell therapies for cancer. “Founded to discover, develop and commercialize curative immune cell therapies,” The San Francisco-based biotech firm has caught the attention of investors for a little more than their innovative flair...